Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dongsheng Tu

Showing results (81-90 of 200) with videos related to

Pageof 20
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 14, 2021
Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17RJosee-Lyne Ethier, Geoffrey M Anderson, Peter C Austin, et al.
Breast Cancer Research and Treatment|November 2, 2011
Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 TrialKathleen I Pritchard, Alison Munro, Frances P O'Malley, et al.
The Oncologist|August 18, 2019
A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229)Stephen Chia, Phillipe L Bedard, John Hilton, et al.
Clinical Trials (London, England)|November 24, 2018
Pilot study of the ability to probabilistically link clinical trial patients to administrative data and determine long-term outcomesAnnette E Hay, Joseph L Pater, Elyse Corn, et al.
Investigational New Drugs|September 12, 2019
A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancerRachel Goodwin, Derek Jonker, Eric Chen, et al.
Cancer|September 9, 2010
Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3Gilda da Cunha Santos, Neesha Dhani, Dongsheng Tu, et al.
Acta Oncologica (Stockholm, Sweden)|February 6, 2014
The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17Dirkje W Sommeijer, Christos S Karapetis, John R Zalcberg, et al.
Investigational New Drugs|November 11, 2019
A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG studySarah Lapointe, Warren Mason, Mary MacNeil, et al.
Journal of Pain and Symptom Management|April 3, 2007
A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patientsDeborah J Dudgeon, Eduardo Bruera, Bruno Gagnon, et al.
Cancer Medicine|October 25, 2022
Clustering on longitudinal quality-of-life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trialJiahui Zhang, Weili Kong, Pingzhao Hu, et al.
Pageof 20

Showing results (81-90 of 200) with videos related to

Sort By:
Pageof 20
European Journal of Cancer (Oxford, England : 1990)|April 14, 2021
Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17RJosee-Lyne Ethier, Geoffrey M Anderson, Peter C Austin, et al.
Breast Cancer Research and Treatment|November 2, 2011
Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 TrialKathleen I Pritchard, Alison Munro, Frances P O'Malley, et al.
The Oncologist|August 18, 2019
A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229)Stephen Chia, Phillipe L Bedard, John Hilton, et al.
Clinical Trials (London, England)|November 24, 2018
Pilot study of the ability to probabilistically link clinical trial patients to administrative data and determine long-term outcomesAnnette E Hay, Joseph L Pater, Elyse Corn, et al.
Investigational New Drugs|September 12, 2019
A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancerRachel Goodwin, Derek Jonker, Eric Chen, et al.
Cancer|September 9, 2010
Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3Gilda da Cunha Santos, Neesha Dhani, Dongsheng Tu, et al.
Acta Oncologica (Stockholm, Sweden)|February 6, 2014
The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17Dirkje W Sommeijer, Christos S Karapetis, John R Zalcberg, et al.
Investigational New Drugs|November 11, 2019
A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG studySarah Lapointe, Warren Mason, Mary MacNeil, et al.
Journal of Pain and Symptom Management|April 3, 2007
A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patientsDeborah J Dudgeon, Eduardo Bruera, Bruno Gagnon, et al.
Cancer Medicine|October 25, 2022
Clustering on longitudinal quality-of-life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trialJiahui Zhang, Weili Kong, Pingzhao Hu, et al.
Pageof 20